Rationale To facilitate in vivo characterization of the mu antagonist Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH 2 (CTAP), the present study characterized CTAP selectivity in vivo. Objectives CTAP, the classical antagonist naltrexone, the kappa-selective antagonist nor-binaltorphimine (BNI), and the delta-selective antagonist naltrindole were compared as antagonists of representative mu, kappa, and delta agonists in a warm water tail-withdrawal assay. Materials and methods Male Sprague-Dawley rats were pretreated with CTAP (0.01 to 10.0 μg, i.c.v.), naltrexone (0.1 to 10 mg/kg s.c.; 0.1 to 10 μg i.c.v.), nor-BNI (1 mg/kg s.c.), or naltrindole (0.01 to 1 μg, i.c.v.) and tested with cumulative doses of agonist in 50 or 55°C tail-withdrawal assays. Results At 55°C, morphine and DAMGO produced dosedependent antinociceptive effects that were antagonized by CTAP or naltrexone (s.c. or i.c.v.) in a surmountable, dosedependent manner. Neither kappa agonists (bremazocine, spiradoline, U69,593; all s.c.) nor the delta agonist DPDPE (i.c.v.) produced antinociception at 55°C, but all produced full antinociception at 50°C. CTAP did not antagonize effects of spiradoline, U69,593, or DPDPE, whereas nor-BNI produced insurmountable antagonism of effects of kappa agonists, and naltrindole produced surmountable antagonism of effects of DPDPE. Apparent pA 2 estimates for naltrexone, CTAP, and naltrindole agreed with published estimates, although Schild slopes diverged from predictions for simple competitive antagonism. Conclusions CTAP produces dose-dependent antagonism selective for mu-agonist effects in a standard 55°C tail withdrawal antinociceptive assay.
Introduction
Studies with competitive antagonists are a key tactic to identify functional roles of mu opioid systems. The classical opiate antagonists naloxone and naltrexone have high affinity for mu receptors, but only 3-to 100-fold selectivity for mu relative to kappa or delta opioid receptors (Magnan et al. 1982; with long-lasting effects in functional assays. Three octapeptides, CTP (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH 2 ), CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH 2 ), and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH 2 ), show promise as competitive mu-selective antagonists.
In binding assays, CTP, CTOP, and CTAP show high affinity and exceptional selectivity for mu receptors Kazmierski et al. 1988) . In functional assays in guinea pig ileum (GPI) and mouse vas deferens (MVD), CTOP and CTAP exert potent antagonist actions selective for mu receptors (Kramer et al. 1989; Mulder et al. 1991) . CTP exerts potent and selective mu antagonism in the GPI but also agonist actions at delta opioid and/or somatostatin receptors in the MVD (Shook et al. 1987) . In vivo, all three octapeptides display little agonist activity but rather act as competitive mu antagonists in noxious thermal antinociception assays (Guyla et al. 1988; Kramer et al.1989) . Of the three, CTAP shows the most promise as a useful selective competitive mu-antagonist devoid of intrinsic activity, displaying potent and highly selective mu receptor binding in vitro and in vivo (Gulya et al. 1986; Kazmierski et al. 1988 ) and functional antagonism in bioassays (Kramer et al. 1989) .
Only limited information is available, however, about the ability of CTAP to antagonize delta or kappa receptor agonist effects in vivo. In radiant-heat tail-flick assays in mice and warm water tail-withdrawal and hotplate assays in rats, CTAP acts not only as a potent antagonist of antinociceptive effects of mu agonists (Kramer et al. 1989; He and Lee 1998; Sterious and Walker 2003) but also as an antagonist of antinociceptive effects of the delta agonist DPDPE in mice (Kramer et al. 1989; He and Lee 1998) . Blockade of DPDPE effects may not reflect delta antagonist actions, however, as antagonism of DPDPE appeared noncompetitive in the hotplate assay (Kramer et al. 1989) , and DPDPE effects in the tail-flick assay may be mediated via spinal mu opioid receptors (cf. Matthes et al. 1996; Sora et al. 1997) .
To characterize the selectivity of CTAP as an antagonist in vivo, we compared the ability of CTAP to act as an antagonist to antinociceptive effects of mu, kappa, or delta opioid receptor agonists in a warm water tail-withdrawal assay in rats. Control experiments compared effects of CTAP to those of the classical antagonist naltrexone, the kappa-selective antagonist nor-binaltorphimine, and the delta-selective antagonist naltrindole. In addition, given the different chemical compositions of mu agonists (alkaloid versus peptide) and the constraints on their routes of administration, CTAP and naltrexone were examined for their ability to antagonize effects of morphine and DAMGO given i.c.v. The 55°C warm water tail-withdrawal assay was chosen because it readily identifies morphine-like narcotics (Janssen et al. 1963 ) and has greater sensitivity to analgesic actions of mu agonists as compared to kappa or delta agonists, which are relatively inactive (Adams and Holtzman 1990; Adams et al. 1994 ) unless stimulus intensity is decreased. In light of this, a 50°C tail-withdrawal assay was used to assess antagonist effects against kappa or delta agonists. Apparatus Before initiation of studies, rats were trained to lie quietly in Harvard Apparatus rodent restraint tubes in a quiet room. Tap water was heated to 75°C in a Precision model 181 water bath; water temperatures of 40, 50, or 55°C were obtained by mixing heated and tap water in a Thermos® flask (diameter=8 cm). Water temperature was measured by a Sensortek model BAT-12 with a Bailey/Sensortek Type T thermocouple. Tail-withdrawal latencies were observed visually and recorded with a hand-operated digital stopwatch (resolution=1/100 s).
Materials and methods

Subjects
Surgery Rats were anesthetized with pentobarbital (25 mg/ kg, i.p.) and ketamine (5 mg/kg, i.m.), and given atropine (0.4 mg/kg, s.c.) to reduce bronchial secretions. Each rat was placed in a small animal stereotaxic apparatus (David Kopf Instruments), and a 5.5 mm stainless steel cannula (22 gauge; Plastic Products) was implanted in the left ventricle (coordinates: AP=−0.8; ML=1.5; DV=−3.6 from bregma; Paxinos and Watson 1986) . Cannula patency was verified 1 week after surgery and at approximately 6-week intervals thereafter. A cannula was considered patent if a rat drank within 1 min and consumed at least 14 g of water in 0.5 h after 8 μg angiotensin II, i.c.v. Once a cannula tested as non-patent, a rat was not used for further i.c.v. tests. Placement was verified by i.c.v. injection of 1 μl India ink followed by euthanasia and gross dissection of coronal slices at the level of the lateral ventricles.
Tail-withdrawal procedure A cumulative dose test procedure, in which tail-withdrawal latency was measured in short successive trials (Walker et al. 1994) , was used to estimate potency and maximal effects of agonists. A rat was weighed, placed into a restraint tube with tail hanging freely, and the distal 5 to 10 cm of the tail was immersed in water of the desired temperature. To prevent tissue damage, a cut-off time of 15 or 20 s was imposed at the 55 or 50°C temperature, respectively. If the rat did not withdraw its tail before the cut-off time elapsed, the experimenter removed the stimulus. At the start of every test, a temperature of 50 or 55°C was presented, followed, to control for tail withdrawal independent of water temperature, by two to four presentations of 40°C water at 2-min intervals. A rat that did not withdraw the tail within the cut-off interval on two out of four presentations of 40°C qualified for a test.
After qualifying for the test, the rat was removed from the restraint tube, injected with vehicle or an appropriate antagonist, and returned to the tube. After a 15-min pretreatment period (20 min for bremazocine), tail-withdrawal latencies were measured at 55°C (or 50°C). At the end of the 5-min test period, a second injection was given. Cumulative doses of agonist were injected before this and all subsequent trials, with doses increased by 0.25 to 0.50 log units. Trials continued until a limit of cut-off time solubility, i.c.v. volume, or antagonist duration was reached, or until another behavior (i.e., convulsions) interfered with measurement.
Tests were conducted approximately every 7 days. At the outset, all rats received at least three tests of morphine, s.c., at 55°C to determine reproducibility of effects, at least one test of consecutive vehicle injections to assess changes over successive trials, and a test of morphine after pretreatment with 0.1 mg/kg naltrexone, s.c. Thereafter, tests of agonists alone alternated with tests preceded by injection of antagonists: naltrexone (0.01, 0.1, 1.0, or 10.0 mg/kg, s.c.; 0.1, 1.0, or 10 μg/rat i.c.v.; −15 min), CTAP (0.1, 1.0, or 10 μg, i.c.v.; −15 min), nor-binaltorphimine (nor-BNI; 1.0 mg/kg, s.c.; −24 h), or naltrindole (1.0 μg, i.c.v.; −15 min). In pilot experiments (not shown), all antagonists except nor-BNI were active within 15 min, and naltrexone had the shortest duration of action, which decayed after 90 min. Agonist dose-effect functions that required more than six trials (90 min) were determined by tests of overlapping dose ranges. Each rat participated in 12-20 tests over 6 months or until loss of cannula patency and/or euthanasia for reasons unrelated to the experiment. Periodic tests of morphine alone were conducted to ascertain changes in agonist sensitivity.
Tests To assess the ability of CTAP (i.c.v.) to antagonize antinociceptive effects of mu, kappa, or delta agonists, effects of the mu agonists morphine (s.c. and i.c.v.) and DAMGO (i.c.v.) , the kappa-selective agonists spiradoline, bremazocine, and U69,593 (all s.c.), and the delta-selective agonist DPDPE (i.c.v.) were determined alone and after i.c.v. pretreatment with CTAP. Representative agonists were also tested after s.c. or i.c.v. pretreatment with the prototypic opioid antagonist naltrexone. Rats were randomly assigned to groups (N=5 to 11), and each group received multiple tests either of CTAP and agonist, or naltrexone (s.c., then i.c.v.) and agonist. To the extent possible, agonists were studied in the following order: morphine (s.c., then i.c.v.), DAMGO; morphine, DAMGO, spiradoline; morphine, bremazocine, U69,593, morphine, DPDPE. To verify that kappa or delta agonists were indeed susceptible to a selective antagonist, rats tested with these agonists received a final test that utilized a single administration of a selective kappa or delta antagonist (nor-BNI or naltrindole).
Data analysis Latencies were converted to percent maximum effect by the formula:
using the control latency measured at the beginning of each cumulative dose test. Each rat served as its own control. All dose-response curves for individual rats, in absence or presence of antagonist, were fitted using the semilogarithmic form of the logistic dose-response equation:
where E is % MPE. Because equilibrium conditions cannot be ensured in vivo, analyses focused on changes in agonist potency to produce 50% MPE (Christopoulos et al. 1999) , and Emin and Emax were set at 0 and 100. A is the dose of agonist (in mg/kg or μg/rat), ED 50 is the agonist dose causing 50% MPE, and h is the Hill slope. For each test, log ED 50 values were averaged across subjects and a 95% CL calculated with the t statistic. To assess magnitude and dose-dependency of antagonist effects, a potency ratio was calculated for each rat by dividing the ED 50 in the presence of antagonist by the ED 50 in the absence of antagonist. For experiments in which agonists produced ≥ 50% MPE when combined with antagonists, antagonist potencies were assessed with three procedures, with antagonist doses converted to moles/kg. First, Schild analyses of potency ratios for individual rats were used to derive apparent in vivo estimates of pA 2 , the negative logarithm of the mole/kg dose of antagonist that increases, by a factor of 2, the agonist dose required to produce a 50% MPE (Arunlakshana and Schild 1959; Tallarida 1982) ; fits of regression lines with unconstrained or −1 slopes were compared by F test. Then, two alternative analyses were conducted because, although repeated tests of morphine (s.c.) revealed few time-dependent changes in sensitivity, parallel time controls were not conducted. Therefore, data were re-analyzed with two nonlinear techniques that do not require dose ratios. In the first (Lew and Angus 1995) , agonist ED 50 values and antagonist doses were used to fit the following equation:
ÀpA 2 ÃSchildSlope ÀP;
where B=antagonist dose, in moles/kg, and P is a fitting constant equal to the logarithm of the ratio of the control agonist EC50 to the estimated pA 2 /SchildSlope (Christopoulos et al. 1999) . To test conformity to a model of competitive antagonism, the fit of this equation was compared by F test to its fit when SchildSlope=1. In the second nonlinear technique (Motulsky and Christopoulos 2003) , % MPE data for each set of agonist-antagonist combinations were fit simultaneously to a modified Gaddum/Schild equation,
with variables as above. Note that in the absence of antagonist (Log[B]=0), this equation is the four-parameter logistic equation used to fit agonist dose-response data. Parallelism of agonist dose-response curves in presence and absence of antagonist was assessed by F test, which compared a fit in which the h parameter was shared among each set of curves with a fit in which each curve was allowed its own h factor. F tests also tested whether the Schild slope for each set of curves differed from unity. For the rare sets of curves for which this was not the case, the curves were refitted with the SchildSlope parameter constrained to a value of 1. All data and statistical analyses were performed with GraphPad Prism (version 4.03 for Windows, GraphPad Software, San Diego, CA, USA, www.graphpad.com). P< 0.05 was considered significant.
Drugs Morphine sulfate, CTAP, and naltrexone hydrochloride were obtained from the National Institute on Drug Abuse, Rockville, MD. DAMGO was purchased from Sigma Chemical, St. Louis, MO. Spiradoline mesylate, bremazocine, U69,593 (5alpha, 7alpha, 8beta-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl]benzeneacetamide), nor-BNI, DPDPE, and naltrindole were purchased from Research Biochemicals, Natick, MA. Drugs administered s.c. were dissolved in physiological saline, except for spiradoline, which was dissolved in sterile water. Solutions were prepared to administer each s.c. injection in a volume of 0.1 to 2.0 ml/100 g body weight, and injections were administered in the dorsal flank. Drugs administered i.c.v. were dissolved in sterile water and were delivered via Hamilton syringe at a rate of 1 μl over 30 to 60 s. Solutions were prepared to administer each i.c.v. injection in a volume of 1.0 to 4.0 μl per injection, with the total volume per test not to exceed 20 μl.
Results
Stability and reproducibility of agonist sensitivity To assess reproducibility of tail withdrawal latencies, all rats received multiple tests of morphine, s.c., before and after cannula implantation, and tests of consecutive vehicle injections (data not shown). These controls indicated that the potency of morphine decreased two-to threefold over the first two or three tests but remained stable thereafter, and that sensitivity to antinociceptive effects of morphine differed among groups of rats. Tests of multiple vehicle injections demonstrated that the repeated injection procedure itself did not change latencies. Additionally, no differences were observed in maximal effects of morphine or its potency before or after surgical implantation of cannulae. Pretreatment with 0.1 mg/kg naltrexone increased the morphine ED 50 by tenfold, indicating robust antagonism of antinociceptive effects of morphine in all rats.
Antagonism of mu-agonist effects When given s.c., morphine produced dose-dependent antinociceptive effects in the 55°C assay, yielding maximal effects at 10.0 to 32 mg/ kg (Figs. 1 and 2, left) suggested that naltrexone potency varied with route of administration. First, naltrexone was more potent when given i.c.v. than when given s.c. Second, when given i.c.v., naltrexone was more potent against mu agonists given i.c.v. than s.c. These trends were evident independent of analysis, but comparisons utilizing dose ratios (i.e., Schild analyses; ICV administration of CTAP also produced surmountable, dose-dependent antagonism of antinociceptive effects of morphine and DAMGO at 55°C (Fig. 1, bottom) . Quantitative comparisons (Table 1) suggested that CTAP was more potent as an antagonist of central than of peripheral morphine, accompanied, at only the highest dose, by a loss of maximal morphine effect. CTAP was more potent as an antagonist of morphine given i.c.v. than of DAMGO given i.c.v., but latter data were highly variable. Antagonism was directly proportional to CTAP dose (i.e., described by a Schild slope of −1) in only three instances, and in only one instance for all analyses of a combination, but all analyses yielded slopes indicative of antagonism.
Antagonism of kappa agonist effects Kappa agonists did not exert antinociceptive effects at 55°C (not shown), so stimulus intensity was decreased to 50°C, at which all exerted full antinociceptive effects. Antinociceptive effects of peripherally administered spiradoline or U69,593 were not antagonized by any dose of CTAP, whereas those of bremazocine were antagonized only by the highest dose of CTAP (Fig. 2, middle) . Effects of bremazocine and spiradoline, but not those of U69,593, were antagonized by doses of naltrexone (Fig. 2, top) higher than those effective against effects of mu agonists. Nor-BNI (1.0 mg/ kg, s.c., 24 h; Fig. 2 , bottom) produced profound antagonism of antinociceptive effects of all kappa agonists. As a check of antagonist actions of CTAP or naltrexone at 50°C, each was tested against morphine, given s.c. Morphine elicited full antinociceptive effects, and both naltrexone (s.c.) and CTAP exerted surmountable antagonism. Naltrexone potency was lower at 50°C than at 55°C, whereas CTAP potency was slightly higher (Table 1) . As a final test of whether rats tested with kappa agonists were sensitive to CTAP antagonism of mu effects, all were tested with morphine after pretreatment with 10 μg CTAP. CTAP increased the morphine ED 50 by approximately tenfold, yielding a pA 2 estimate similar to that from tests with a full range of CTAP doses.
Antagonism of delta agonist effects DPDPE produced no antinociceptive effects at 55°C but full effects at 50°C. CTAP did not antagonize the antinociceptive effects of DPDPE at any dose (Fig. 3) . When given s.c., naltrexone produced dose-dependent antagonism of DPDPE effects, with a potency lower than against mu agonists. Naltrindole, i.c.v., dose-dependently antagonized effects of DPDPE, and all analyses yielded similar potency estimates (Table 1) .
Comparisons among analyses Apparent in vivo pA 2 estimates for antagonists that produced surmountable antagonism of agonist effects were calculated by Schild analysis and by two non-linear techniques (Table 1) . Few analyses yielded Schild slopes of −1, but all with Schild slopes different from 0 yielded defined confidence intervals, indicating that our assay conditions were sensitive to dose-dependent effects of antagonists. Schild analysis, which uses dose ratios, yielded larger confidence intervals than did analyses focused on either agonist ED 50 doses or families of agonist dose-response functions. The latter analyses, which incorporated the most information from the dose-effect functions, yielded smallest confidence limits for both pA 2 values and slope.
Discussion
CTAP dose-dependently antagonized in vivo antinociceptive effects of morphine and DAMGO, but not those of kappa or delta agonists in a warm water tail-withdrawal assay. Parallel experiments demonstrated that kappa and delta agonists were sensitive to appropriate selective antagonists and that CTAP antagonized actions of morphine under assay conditions required for kappa or delta agonist activity. Taken together, these results suggest that CTAP acts as a selective mu opioid antagonist in vivo.
Initial experiments assessed antagonist effects of the classical antagonist naltrexone. Naltrexone dose-dependently antagonized antinociceptive effects of mu, delta and, with exception of U69,593, kappa agonists. As expected, potency of s.c. naltrexone, as assessed by apparent pA 2 values, was higher against mu agonists than against kappa or delta agonists. Potency estimates for s.c. naltrexone were similar to those reported for antagonism of antinociceptive effects of mu agonists in mice or rats (Garner et al. 1997; Sterious and Walker 2003) but lower than values reported for antagonism of effects of kappa agonists in mice or primates (Garner et al. 1997; Ko et al. 1998; Powell and Holtzman 1999) . When given i.c.v. rather than s.c., naltrexone potency increased 30-to 300-fold as an antagonist of either s.c. morphine (apparent pA 2 values of 9.4 vs 7.9) or i.c.v. morphine (10.6 vs 8.2), whereas potency as an antagonist of i.c.v. DAMGO increased 10,000-fold (11.5 vs 7.2). In contrast, Sterious and Walker (2003) reported no difference in potency of i.c.v. or s.c. naltrexone as an antagonist of s.c. morphine under similar Fig. 3 Antagonism of antinociceptive effects of the delta agonist DPDPE by naltrexone (top, −15 min, s.c.), CTAP (middle, −15 min, i.c.v.), or naltrindole (bottom, −15 min, i.c.v.) in a 55°C tail-withdrawal assay. Each combination was studied in eight rats. Other details as in Fig. 1 assay conditions. The lack of antagonism of effects of the kappa agonist U69,593 by even 10 mg/kg naltrexone was unexpected, in light of naltrexone antagonism of similar effects of bremazocine and spiradoline in the present study and reports that naltrexone is an effective antagonist of U69,593 effects in mice and primates (Millan et al. 1989; Ko et al. 1998; Powell and Holtzman 1999) at doses effective against other kappa agonists.
CTAP dose-dependently antagonized antinociceptive effects of mu-opioid agonists but, with one exception, not of kappa-or delta-opioid agonists in the warm water tailwithdrawal assay. CTAP was nearly 100-fold more potent than s.c. naltrexone as an antagonist of s.c. morphine (pA 2 values of 9.8 vs 7.9). CTAP was equi-potent to i.c.v. naltrexone as an antagonist of s.c. morphine (9.8 vs 9.4) but was 100-fold more potent as an antagonist of i.c.v. morphine (12.4 vs 10.6). Our results for CTAP were similar to those reported by Sterious and Walker (2003) for the same agonists and routes of administration, indicating greater CTAP potency in vivo than found for in vitro assays such as the GPI (Kramer et al. 1989) .
The potency differences between naltrexone and CTAP as antagonists of mu agonists may arise from several sources. First, CTAP may possess higher affinity for receptors mediating antinociceptive effects of the mu agonists tested. Second, route of administration may impact potency estimates. Antinociceptive effects of mu-opioid agonists are mediated through both spinal and supraspinal mu receptor populations (Narita et al 2002; Chow et al. 2004; Goodchild et al 2004) , and central administration may increase the probability of drug-receptor interactions, thereby increasing apparent potency. Third, use of a broad range of antagonist doses against all agonists, done to minimize the likelihood of differences across agonists due to direct effects, may have limited the applicability of the theoretical model. In particular, use of high antagonist doses may have revealed non-mu opioid, or even non-opioid, effects of agonists, leading to an underestimate of dose ratios for agonist effects (Zhang et al. 2000) . Finally, it is unlikely that drugs were tested under equilibrium conditions. Schild slopes differed from −1, suggesting mechanisms other than one-toone competition for a single receptor population. This argues caution in using in vivo apparent pA 2 values as estimates of affinity (cf. Contreras et al. 1986 ), but does not preclude use of pA 2 values as empirical estimates of antagonist potency (cf. Motulsky and Christopoulos 2003) .
CTAP did not antagonize antinociceptive effects of the kappa agonists spiradoline or U69,593, and antagonized effects of bremazocine at doses 100 to 10,000 times higher than required to antagonize effects of mu agonists. Kappa agonists did not produce antinociceptive effects at 55°C, confirming reports that kappa agonists are less effective than mu agonists in the warm water tail-withdrawal assay when noxious stimulation is intense (Tyers 1980; Heyman et al. 1988; Fanselow et al. 1989; Millan et al. 1989; Millan and Colpaert 1990; Adams et al. 1994) . When stimulus intensity was reduced to 50°C, all kappa agonists elicited maximal antinociceptive effects, which were fully antagonized by the kappa-preferring antagonist nor-BNI. Antagonism by nor-BNI was insurmountable at the kappa agonist doses tested, and competing behaviors prevented tests of higher doses. CTAP acted to antagonize mu agonist effects in rats insensitive to CTAP antagonism of kappa agonist effects, ruling out individual differences as a source of inactivity against kappa agonists.
CTAP also did not antagonize antinociceptive effects of the delta-selective agonist DPDPE. DPDPE did not produce antinociceptive effects at 55°C but produced full antinociceptive effects at 50°C. These effects were not antagonized by CTAP but were dose-dependently antagonized by naltrexone at doses 10-to 100-times greater than those required for antagonism of mu-agonist effects. Effects of DPDPE were also antagonized by the delta-selective antagonist naltrindole, with a potency in agreement with published reports (Crook et al. 1992; Portoghese et al. 1992; Chakrabarti et al. 1993; Stamidis and Young 1993; Tiseo and Yaksh 1993) . In contrast with reports that i.c.v. or intrathecal DPDPE may elicit antinociception via CTAPsensitive sites in mice (Kramer et al. 1989; He and Lee 1998) , the potency of naltrindole, reduced potency of naltrexone, and lack of antagonism by CTAP in the present study suggest that antinociceptive effects of i.c.v. DPDPE in the 50°C tail-withdrawal assay arose primarily from actions at delta sites.
Our analyses of antagonist potency used apparent in vivo pA 2 estimates derived from Schild analyses (Arunlakshana and Schild 1959) and two nonlinear techniques (Lew and Angus 1995; Motulsky and Christopoulos 2003) . The latter techniques minimize contributions of agonist potency in the absence of antagonist to potency calculations and generate smaller confidence limits, and thus may be preferable for in vivo potency estimates. It is important to note that any use of apparent pA 2 values to describe potency of antagonists in vivo involves assumptions (Dykstra and Massie 1988) that the antagonist has no agonist effects in the test system, that agonist and antagonist interact in a surmountable, competitive manner, and that both are at equilibrium. Agonist effects were not observed for any antagonist in our assays, and shifts in agonist dose-effect functions were parallel (although rarely exactly proportional to antagonist dose), but our cumulative dosing procedures may not have matched times of peak drug activity.
For an antagonist with affinity for multiple receptor types, differences in relative antagonist potency can differentiate among agonists selective for different receptor subtypes (Takemori 1973; Dykstra and Massie 1988) , suggesting that differences in relative potency as measured by apparent pA 2 analysis are indicative of differences in receptors mediating a biological effect. Similarly, antagonists with high affinity for a receptor population have higher apparent pA 2 values for effects mediated via that receptor type as compared to antagonists with lower affinity for that receptor type Woods 1987, 1989) . The present results suggest that the greater affinity of CTAP for mu as opposed to kappa or delta opioid receptors in vitro (Gulya et al. 1986; Kazmierski et al. 1988 ) results in selectivity of antagonist actions in vivo. Biochemical and in vivo experiments suggest that CTAP may function as a neutral antagonist, devoid of ability to precipitate abstinence in dependent organisms (Bilsky et al. 1996; Wang et al. 2001) . While the present experiments did not evaluate the neutral antagonist profile of CTAP, the clear selectivity of CTAP antagonist actions will enable such characterization.
